Skip to main content
. 2019 Dec 16;23(2):207–219. doi: 10.1038/s41391-019-0195-5

Fig. 2. Comparison of second generation antiandrogens in preclinical studies.

Fig. 2

a Serum testosterone levels (nmol/L ± SEM) of mice models of VCaP tumors after oral treatment with vehicle, enzalutamide (20 mg/kg, qd), or darolutamide (50 mg/kg, bid) for 3 weeks (n = 8). *P < 0.05 vs. vehicle. b Mean brain–plasma ratios (%) in mice after oral treatment with darolutamide (25, 50, or 100 mg/kg, bid for 7 days), enzalutamide (20 mg/kg, qd for 7 days; n = 5), or apalutamide (a single dose of 10 mg/kg; n = 3). *Evaluated from different concentrations of darolutamide. bid twice daily, qd once daily, SEM standard error of the mean. [Reproduced from Moilanen, et al. 2015 [54] https://www.nature.com/articles/srep12007 (drug names updated)].